Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

CervoMed Inc.

CIK 1053691 CRVO·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. SEC comment letter CORRESP
  2. Going concern 10-K +30d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

CervoMed Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure Substantial doubt about ability to continue as a going concern

The Company’s ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and will be required to raise additional capital to fund operations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 2. The financial statements do not include any adjustments that might result from the…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-03-17
Prior form
10-K
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
SEC comment letter Filing comparison

CervoMed Inc. responded to SEC staff comments on MD&A

Letter dated 2025-09-23; published on EDGAR 2026-02-11 — the SEC releases comment letters only after the review closes.

Evidence
Direction
company to staff
Letter dated
2025-09-23
Published on edgar
2026-02-11
Reviewing
CervoMed Inc. Form 10-K for the year ended December 31, 2024 Filed March 17, 2025 File No. 001-37942 Ladies and Gentlemen: We are submitting this letter on beha
Source
Company response to SEC staff (CORRESP)
Topics
MD&A, Share-based compensation
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.
SEC comment letter Filing comparison

SEC staff questioned CervoMed Inc.'s accounting for MD&A

Letter dated 2025-09-12; published on EDGAR 2026-02-11 — the SEC releases comment letters only after the review closes.

Evidence
Direction
staff to company
Letter dated
2025-09-12
Published on edgar
2026-02-11
Reviewing
CervoMed Inc. Form 10-K for the year ended December 31, 2024 Filed March 17, 2025 File No. 001-37942 Dear William Elder: We have reviewed your filing and have t
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.